Indivior PLC (LON:INDV) Given Buy Rating at Numis Securities Ltd

Numis Securities Ltd reiterated their buy rating on shares of Indivior PLC (LON:INDV) in a research report released on Friday, September 15th. Numis Securities Ltd currently has a GBX 470 ($6.32) price target on the specialty pharmaceutical company’s stock.

Several other research analysts also recently commented on the stock. Citigroup Inc. reissued a neutral rating and set a GBX 280 ($3.77) price objective on shares of Indivior PLC in a report on Tuesday, September 5th. Jefferies Group LLC reissued a buy rating and set a GBX 490 ($6.59) price objective on shares of Indivior PLC in a report on Wednesday, June 7th. Royal Bank Of Canada reissued an outperform rating and set a GBX 470 ($6.32) price objective on shares of Indivior PLC in a report on Thursday, August 3rd. Finally, Stifel Nicolaus reissued a buy rating and set a GBX 400 ($5.38) price objective on shares of Indivior PLC in a report on Friday, September 15th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of GBX 395.50 ($5.32).

Shares of Indivior PLC (INDV) opened at 329.00 on Friday. Indivior PLC has a 52-week low of GBX 246.50 and a 52-week high of GBX 421.50. The firm’s 50-day moving average price is GBX 367.14 and its 200-day moving average price is GBX 335.73. The stock’s market cap is GBX 2.37 billion.

WARNING: This news story was first reported by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/indivior-plc-indv-given-buy-rating-at-numis-securities-ltd/1646772.html.

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with our FREE daily email newsletter.

 


Latest News

Bryce Harper Hoping to Return Monday from Knee Injury
Bryce Harper Hoping to Return Monday from Knee Injury
American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?


Leave a Reply

 
© 2006-2017 BBNS.